IRWDIronwood Pharmaceuticals, Inc.

$629M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M-7.6% YoY

Gross Profit

$116M99.2% margin

Operating Income

$51M44.0% margin

Net Income

$43M37.0% margin

EPS (Diluted)

$0.27

QoQ Revenue Growth

+12.8%

Cash Flow

Operating Cash Flow

$52M

Free Cash Flow

$51M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$559M

Total Liabilities

$497M

Stockholders' Equity

$63M

Cash & Equivalents

$364M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$126M	-7.6%
Gross Profit	$116M	$115M	+0.4%
Operating Income	$51M	$50M	+3.6%
Net Income	$43M	$48M	-9.7%

Revenue Segments

Collaborative Arrangement Co Promotion Agreement

$1M63%

Collaborative Arrangement Promotion Agreement

$400,00021%

Royalty

$300,00016%

Geographic Segments

North America

$605,00025%

Europe And Other

$603,00025%

Europe

$600,00025%

Canada And Mexico

$600,00025%

IRWD Q4 2020 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena